Graphite Bio Files 8-K Report
Ticker: LENZ · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1815776
| Field | Detail |
|---|---|
| Company | Graphite Bio, Inc. (LENZ) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
TL;DR
Graphite Bio filed an 8-K, mostly boilerplate for now.
AI Summary
On March 19, 2024, Graphite Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and includes a Regulation FD Disclosure. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate reporting, but without specific details, its immediate impact on investors is unclear.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediately apparent negative or positive material information disclosed.
Key Players & Entities
- Graphite Bio, Inc. (company) — Registrant
- 001-40532 (company) — Commission File Number
- 83-4867570 (company) — I.R.S. Employer Identification No.
- 611 Gateway Boulevard, Suite 120, South San Francisco, California 94080 (company) — Principal executive offices address
- Integral Medicines, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Graphite Bio, Inc.?
The filing is a Current Report (8-K) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on March 19, 2024, and includes information on Financial Statements and Exhibits, as well as a Regulation FD Disclosure.
When was Graphite Bio, Inc. incorporated or organized?
The filing states the company is incorporated in Delaware.
What is Graphite Bio, Inc.'s fiscal year end?
The company's fiscal year ends on December 31.
What was Graphite Bio, Inc.'s former company name?
The former company name was Integral Medicines, Inc., with a date of name change on June 22, 2020.
What is the business address and phone number for Graphite Bio, Inc.?
The business address is 611 Gateway Boulevard, Suite 120, South San Francisco, California 94080, and the telephone number is (502) 398-9250.
Filing Stats: 1,637 words · 7 min read · ~5 pages · Grade level 17 · Accepted 2024-03-19 16:31:05
Key Financial Figures
- $0 — res of Graphite common stock, par value $0.00001, per share of Graphite (" Common
Filing Documents
- d780027d8k.htm (8-K) — 34KB
- 0001193125-24-071353.txt ( ) — 160KB
- grph-20240319.xsd (EX-101.SCH) — 3KB
- grph-20240319_lab.xml (EX-101.LAB) — 18KB
- grph-20240319_pre.xml (EX-101.PRE) — 11KB
- d780027d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Forward-Looking Statements
Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed merger by and between Graphite and LENZ; the combined company's listing on Nasdaq after the closing of the proposed Merger; expectations regarding the ownership structure of the combined company; the expected executive officers and directors of the combined company; expectations regarding the structure, timing and completion of a concurrent private financing, including investment amounts from investors, timing of closing, expected proceeds and impact on ownership structure; each company's and the combined company's expected cash position at the closing of the Merger (the " Closing ") and cash runway of the combined company following the Merger and private financing; the future operations of the combined company, including commercialization activities, timing of launch and buildout of commercial infrastructure; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company, including expectations around market exclusivity and IP protection; the location of the combined company's corporate headquarters; anticipated clinical drug development activities and related timelines, including the expected timing for announcement of data and other clinical results and potential submission of a New Drug Application for one or more product candidates; and other statements that are not historical fact. All statements other than statements of historical fact contained in this communication are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, foreca